Ultifend ND IBD


Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)

This medicine is authorised for use in the European Union.


Ultifend ND IBD is a veterinary vaccine used to protect chickens against three separate viral diseases: Newcastle disease (ND), infectious bursal disease (IBD) and Marek’s disease (MD).

ND is a viral infection of chickens which causes gasping and coughing, nervous signs (drooping wings, twisting of the head and neck, circling and paralysis), swelling of the tissues around the eyes and neck, greenish watery diarrhoea and reduced egg production.

IBD (also known as Gumboro disease) is a viral infection of young chickens that reduces their immunity (body’s ability to fight disease) and can lead to their death at 3 to 6 weeks of age. Signs of chickens infected with IBD include trembling, ruffled feathers, poor appetite, dehydration, diarrhoea, huddling and depression. 

MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs. Chickens become infected at an early age via inhalation of dander (flakes of skin) containing the virus, which can remain infectious for several months after being shed from the body. Chickens infected with MD virus can be carriers and shedders of the virus for life.

Ultifend ND IBD contains a live strain of turkey herpesvirus (strain rHVT/ND/IBD) that has been modified to produce proteins from ND virus and IBD virus.

This EPAR was last updated on 21/09/2021

Authorisation details

Product details
Ultifend ND IBD
Agency product number
Active substance
Turkey herpes virus, strain rHVT/ND/IBD, expressing the fusion protein of Newcastle disease virus and the VP2 protein of infectious bursal disease virus, live recombinant
International non-proprietary name (INN) or common name
Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)
  • Embryonated chicken eggs
  • Chicken
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Ceva-Phylaxia Veterinary Biologicals Co. Ltd
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Szállás u. 5
1107 Budapest

Product information

20/04/2021 Ultifend ND IBD - EMEA/V/C/005347 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for aves

Therapeutic indication

For the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by Newcastle disease virus (NDV) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (IBDV); to reduce mortality, clinical signs and lesions caused by classical Marek’s disease virus (MDV).

Assessment history

Related content

How useful was this page?

Add your rating